Fracture nonunion is a severe clinical problem for the patient, as well as for the clinician. About 5-20% of fractures does not heal properly after more than six months, with a 19% nonunion rate for tibia, 12% for femur and 13% for humerus, leading to patient morbidity, prolonged hospitalization, and high costs.

The standard treatment with iliac crest-derived autologous bone filling the nonunion site may cause pain or hematoma to the patient, as well as major complications such as infection.

The application of mesenchymal autologous cells (MSC) to improve bone formation calls for randomized, open, two-arm clinical studies to verify safety and efficacy.

The ORTHOUNION * project (ORTHOpedic randomized clinical trial with expanded bone marrow MSC and bioceramics versus autograft in long bone nonUNIONs) is a multicentric, open, randomized, comparative phase II clinical trial, approved in the framework of the H2020 funding programme, under the coordination of Enrique Gòmez Barrena of the Hospital La Paz (Madrid, Spain).

Starting from January 2017, patients with nonunion of femur, tibia or humerus have been actively enrolled in Spain, France, Germany, and Italy.

The study protocol encompasses two experimental arms, i.e., autologous bone marrow-derived mesenchymal cells after expansion (‘high dose’ or ‘low dose’ MSC) combined to ceramic granules (MBCP™, Biomatlante), and iliac crest-derived autologous trabecular bone (ICAG) as active comparator arm, with a 2-year follow-up after surgery.

Despite the COVID 19 pandemic with several lockdown periods in the four countries, the trial was continued, leading to 42 patients treated out of 51 included, with 11 receiving the bone graft (G1 arm), 15 the ‘high dose’ MSC (200x10⁶, G2a arm) and 16 the ‘low dose’ MSC (100x10⁶, G2b arm).

The Rizzoli Orthopaedic Institute has functioned as coordinator of the Italian clinical centres (Bologna, Milano, Brescia) and the Biomedical Science and Technologies and Nanobiotechnology Lab of the RIT Dept. has enrolled six patients with the collaboration of the Rizzoli’ 3rd Orthopaedic and Traumatological Clinic prevalently Oncologic.

Moreover, the IOR Lab has collected and analysed the blood samples from all the patients treated to monitor the changes of the bone turnover markers following the surgical treatment with G1, G2a or G2b protocols.

The clinical and biochemical results of the study, still under evaluation, are presented.

* ORTHOUNION Horizon 2020 GA 733288

Background

Delayed bone healing and nonunion are complications of long bone fractures, with prolonged pain and disability. Regenerative therapies employing mesenchymal stromal cells (MSC) and/or bone substitutes are increasingly applied to enhance bone consolidation. Within the REBORNE project, a multi-center orthopaedic clinical trial was focused on the evaluation of efficacy of expanded autologous bone marrow (BM) derived MSC combined with a CaP-biomaterial to enhance bone healing in patients with nonunion of diaphyseal fractures. To complement the clinical and radiological examination of patients, bone turnover markers (BTM) were assayed as potential predictors of bone healing or non-union.

The postoperative course of median nerve decompression in the carpal tunnel syndrome may sometimes be complicated by postoperative pain, paresthesias, and other unpleasant symptoms, or be characterized by a slow recovery of nerve function due to prolonged preoperative injury causing extensive nerve damage.

The aim of this study is to explore any possible effects of alpha lipoic acid (ALA) in the postoperative period after surgical decompression of the median nerve at the wrist.

Patients were enrolled with proven carpal tunnel syndrome and randomly assigned into one of two groups: Group A: surgical decompression of the median nerve followed by ALA for 40 days. Group P: surgical decompression followed by placebo. The primary endpoint of the study was nerve conduction velocity at 3 months post surgery, Other endpoints were static 2 point discrimination, the Boston score for hand function, pillar pain and use of pain killers beyond the second postoperative day.

ALA did not show to significantly improve nerve conduction velocity or Boston score. However, a statistically significant reduction in the postoperative incidence of pillar pain was noted in Group A. In addition, static 2 point discrimination showed to be significantly improved by ALA.

Administration of ALA following decompression of the median nerve for carpal tunnel release is effective on nerve recovery, although this is not detectable through nerve conduction studies but in terms of accelerated and improved static two-point discrimination.

The use of ALA as a supplementation for nerve recovery after surgical decompression may be extended to all types of compression syndromes or conditions where a nerve is freed from a mechanical insult.

Furthermore, ALA limits post-decompression pain, including late pericicatricial pain at the base of the palm, the so called pillar pain, which seems to be associated with a reversible damage to the superfical sensitive small nerve fibers.

In conclusion postoperative administration of ALA for 40 days post-median nerve decompression was positively associated with nerve recovery, induced a lower incidence of postoperative pillar pain and was associated with a more rapid improvement of static two-point discrimination. This treatment is well tolerated and associated with high levels of satisfaction and compliance, supporting its value as a standard postoperative supplementation after carpal tunnel decompression.

Delayed bone healing and nonunion are complications of long bone fractures, with prolonged pain and disability. Regenerative therapies employing mesenchymal stromal cells (MSC) and/or bone substitutes are increasingly applied to enhance bone consolidation. The REBORNE project entailed a multi-center orthopaedic clinical trial focused on the evaluation of efficacy of expanded autologous bone marrow (BM) derived MSC combined with a CaP-biomaterial, to enhance bone healing in patients with nonunion of diaphyseal fractures. To complement the clinical and radiological examination of patients, bone turnover markers (BTM) were assayed as potential predictors of bone healing or non-union.

Peripheral blood was collected from patients at fixed time-endpoints, that is at 6,12 and 24 weeks post-surgery for implantation of expanded autologus MSC and bone-like particles. Bone-specific alkaline phosphatase (BAP), C-terminal-propeptide type I-procollagen (PICP), osteocalcin (OC), β-Cross-Laps Collagen (CTX), soluble receptor activator of NFkB (RANKL), osteoprotegerin (OPG) were measured by ELISA assays in blood samples of 22 patients at BM collection and at follow-up visits.

A significant relationship with age was found only at 6 months, with an inverse correlation for CTX, RANKL and OC, and positive for OPG. BTM levels were not related to gender. As an effect of local regenerative process, some BTM showed significant changes in comparison to the baseline value. In particular, the time course of BAP, PICP and RANKL was different in patients with a successful healing in comparison to patients with a negative outcome. The BTM profile apparently indicated a remarkable bone formation activity 12 weeks after surgery. However, the paucity of failed patients in our case series did not allow to prove statistically the role of BTM as predictors of the final outcome.

Blood markers related to bone cell function are useful to measure the efficacy of a expanded MSC-regenerative approach applied to long bone non-unions. Changes of the markers may provide a support to radiological assessment of bone healing.

Summary

Reciprocal metabolic reprogramming of MSCs and osteosarcoma cells influences tumor-stroma cross talk. Drugs targeting Warburg metabolism may define innovative therapeutic approaches in osteosarcoma.

Summary Statement

In this study it has been considered an alternative therapeutic approach to bone resorption diseases by using plant decoctions to improve adherence from patients to the treatment. In this context, Hemidesmus indicus represents a possible therapeutic or adjuvant natural compound.

Metals represent the main components of orthopaedic implants. Being in contact with biological fluids, the metallic alloys used for the fabrication of artificial joints undergo corrosion or degradation, therefore they release ions and molecules. Although these do not have antigenic properties, they bind to protein carriers and may act as haptens eliciting a delayed-type hypersensitivity reaction (DTH). Biomaterial-related hypersensitivity is considered as an immunotoxic effect, although little is known about its clinical incidence and its impact on implant failure. The main question about the sensitivity against metals used in the joint prosthesis concern the cause-effect relation with the implant failure. In metal-exposed workers, the diagnosis of DTH is made in vivo by patch testing. For the occupational exposure standard patch-testing protocols are available, but some concerns exist about their applicability to study the hypersensitivity to metal implants. In this case-control study, a panel of representative haptens was used to assess the incidence of positive patch testing in patients undergoing ‘total hip replacement’ (THR) and ‘total knee replacement’ (TKR). The main goal of this study was to evaluate the validity of this relatively simple and safe procedure in the diagnosis of the hypersensitivity reactions to the implant components.

A consecutive series of 286 individuals was enrolled in the study. Five groups of patients were evaluated: Group A included 75 patients (20 M; 55 F; median age 59) candidates to primary THR or TKR; Group B included 98 patients with loosening of THR (27 M; 71 F; median age 67; median follow up: 102 months); Group C included 53 patients with stable THR (13 M; 40 F; median age 68; median follow up: 60 months); Group D included 40 patients with failed TKR (14 M; 26 F; median age 68; median follow up: 24 months); Group E included 20 patients with stable TKR (4 M; 16 F; median age 70; median follow up: 16 months). Osteoarthritis was the most frequent disease that led to joint replacement (59%), followed by hip dysplasia (19%), and trauma (13%). Patients with rheumatoid arthritis were excluded from the study, as well as patients who assumed cortico-steroids or other immunosuppressive drugs.

Fifty-eight patients (21%) had an additional implant at another site. Hypersensitivity to metals was tested by using the most relevant components of Cobalt-Chromium based alloys (CoCrMo), Ti-based alloys (TiAlV), and bone cements. A drop of each hapten was smeared on the Haye’s chamber test, which was applied to the dorsum of the patient. After 48–72 hours, skin reactions were evaluated and graded as 0 (no reaction), 1 (erythema), 2 (edema), 3 (vesicles), or 4 (bulla).

All patients with a medical history of metal DTH showed positive skin reaction. The incidence of positive patch testing to at least one hapten, as well as the frequency of DTH to metal, resulted significantly higher in patients with TKR, while the incidence of positive skin testing to bone cements was similar in all groups. Group B patients with CoCrMo-THR showed a low frequency of nickel-DTH in comparison to Group A (9% and 22%, respectively). In patients with TiAlV-THR the immune status seemed to be unaffected, and these individuals showed a high incidence of vanadium-DTH (Group A: 8%; Group B: 21%; Group C: 19%; p= 0.04). A high incidence of vanadium hypersensitivity was found also in patients with TKR (Group D: 33%; Group E: 20%). The median duration of the implant resulted significantly lower in patients who had a positive patch testing to metals (71 vs 106 months; p= 0.008).

Our results demonstrated the reliability of the panel used for skin testing, which was able to identify a systemic hypersensitivity status. A remarkable finding concerned the prevalence of DTH related to the metal composition of the implant. A significant low frequency of metal DTH, namely nickel, was found in patients with CoCrMo-failed implant. Because nickel is the most common metal sensitizer and its amount in both CoCrMo and TiAlV alloys is very low, we may consider the incidence of nickel DTH as informative for the immune status of the examined group. In the TiAlV group the immune status seems to be unaffected; on the contrary, theese patients showed a high prevalence of vanadium skin reaction. These results confirm the conclusion of previous studies, where the immunocompromised status of patients who had a CoCrMo had been shown and related to the high serum level of chromium and cobalt. Although the cause-effect relation between DTH and implant failure cannot be established, the hypersensitivity should be considered when deciding what type of prosthesis to use. Either if the sensitization precedes or follows the loosening, it participates in the network of events that are responsible for prosthetic loosening, because contributes to mantain the inflammatory process.